BIOMAT Database Logo BIOMAT Database Logo

Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors. 2011

Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
School of Chemistry, University of Southampton , Highfield, Southampton SO17 1BJ, United Kingdom.

A series of darunavir analogues featuring a substituted bis-THF ring as P2 ligand have been synthesized and evaluated. High affinity protease inhibitors (PIs) with an interesting activity on wild-type HIV and a panel of multi-PI resistant HIV-1 mutants containing clinically observed, primary mutations were identified using a cell-based assay. A number of PIs have been synthesized that show equivalent and greater activity for HIV-1 mutant strains as compared to wild-type HIV-1. The activity on the purified enzyme was confirmed for a selection of analogues.

UI MeSH Term Description Entries

Related Publications

Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors (II).
May 2015, Journal of medicinal chemistry,
Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
April 1998, Bioorganic & medicinal chemistry letters,
Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
August 1996, Journal of medicinal chemistry,
Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
Design of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF Ligands.
April 2011, ACS medicinal chemistry letters,
Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands.
June 2019, Bioorganic & medicinal chemistry letters,
Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors.
April 1993, Journal of medicinal chemistry,
Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
September 2007, Journal of medicinal chemistry,
Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.
January 1993, Journal of medicinal chemistry,
Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
June 2011, Bioorganic & medicinal chemistry letters,
Konrad Hohlfeld, and Cyrille Tomassi, and Jörg Kurt Wegner, and Bart Kesteleyn, and Bruno Linclau
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
April 2006, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!